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and Public Affair, Pﬁzer Australia, Sydney, NSW, AustraliaA B S T R A C TBackground: Meta-analysis for the efﬁcacy and safety data of
thrombin-receptor antagonist (TRA) based on patients with acute
coronary syndrome (ACS) or coronary artery disease (CAD) and indirect
comparisons between TRAs were not available. Objectives: We intended
to synthesize the primary end points based on different patient
populations (ACS or CAD) as well as perform indirect comparison
between two newly invented antiplatelet agents atopaxar and vora-
paxar. Methods: A literature search was performed in MEDLINE,
Embase, and Cochrane Library. Incidences of major adverse cardiovas-
cular events (MACEs) and bleeding events according to thrombolysis in
myocardial infarction were selected as primary outcomes, whereas
adverse effects were considered as secondary outcomes. Corresponding
results were synthesized using Revman 5.1 according to ACS or CAD
cohorts. Results: Among the seven included randomized controlled
trials, the efﬁcacy end points in the TRA treatment group were favorable
compared with placebo. Speciﬁcally, the odds ratio (OR) of MACEs was
0.80 (95% conﬁdence interval [CI] 0.52–1.22) for patients with ACS andee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.01.003
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ndence to: Shu-Chuen Li, MS 108, Medical Sciences0.74 (95% CI 0.53–1.05) for the cohort with CAD. The events of bleeding
were unanimously superior in the placebo arm for both cohorts. The
indirect comparison showed a superior trend in favor of atopaxar over
vorapaxar in occurrences of MACEs (OR 0.93; 95% CI 0.38–1.32), myocar-
dial infarction (OR 0.52; 95% CI 0.13– 0.95), and cardiovascular death (OR
0.82; 95% CI 0.12–4.24) and caused less incidence of bleeding. Conclu-
sions: Besides being more effective than placebo in improving the
incidence of MACEs but with a higher risk of bleeding, TRAs may exert
different effects in patients with ACS and CAD. Indirect comparisons
also suggested that atopaxar might be better than vorapaxar in lowering
the incidence of MACEs, myocardial infarction, and cardiovascular death
and at the same time with lower risks of bleeding.
Keywords: acute coronary syndrome, coronary artery disease, meta-
analysis, randomized controlled trials, thrombin-receptor antagonist.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Antiplatelet regimens such as aspirin and P2Y12 antagonist
clopidogrel with demonstrated desirable effect in inhibiting
platelet activation are recommended for patients with acute
coronary syndrome (ACS) and coronary artery disease (CAD) [1–
3]. Disappointingly, all these agents fail to deactivate thrombin
receptors, which could be the most powerful receptors to mobi-
lize platelets. Consequently, even with the deactivation of the
P2Y12 adenosine diphosphate ADP receptor and TxA2-related
activation pathways, platelets can still exert their role via the
stimulation of thrombin receptors, leading to the aggregation of
platelets and subsequent thrombosis [4].
The advent of competitive protease-activated receptor antag-
onists might be a promising option to block thrombin-inducedplatelet aggregation [5]. The newly invented atopaxar and vor-
apaxar could be regarded as representatives of this family.
Thrombin-receptor antagonist (TRA) is a potent blocker of
thrombin-mediated platelet activation without interfering with
thrombin-mediated cleavage of ﬁbrinogen [6].
The efﬁcacy and safety of these two agents have been inves-
tigated in several clinical trials in different patient cohorts. How-
ever, probably partially because of the limited sample size and
insufﬁcient follow-up, the conclusions are inconsistent across
studies. In fact, a meta-analysis addressing the efﬁcacy and safety
of atopaxar and vorapaxar was reported recently by Capodanno
et al. [7]. In this meta-analysis, patients with CAD or non–ST-
segment elevation ACS with or without planned percutaneous
coronary intervention or a history of atherosclerosis (including
ischemic stroke, myocardial infarction [MI], and peripheral arteryociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conﬂicts of interest with regard to the content of this article.
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diagnosis cohort. The authors concluded that atopaxar and vor-
apaxar could reduce the composite of death, MI, or stroke as
compared with placebo (odds ratio [OR] 0.87; 95% conﬁdence
interval [CI] 0.81–0.92) whereas atopaxar and vorapaxar did not
differ from placebo in terms of the risk of death (OR 0.99; 95% CI
0.09–1.09) or stroke (OR 0.96; 95% CI 0.84–1.10). Comparison between
atopaxar and vorapaxar, however, was not performed in the
analysis. Considering that there were differences between these
two drugs in terms of terminal half-life, metabolism, concentration
that produces 50% inhibition [5], discrepancy in therapeutic effect
and safety proﬁle may exist for patients with different diagnosis,
which necessitates further ascertainment. Therefore, unlike this
published meta-analysis, we intended to synthesize the primary
end points based on different patient populations (ACS or CAD) as
well as perform indirect comparison between these two newly
invented antiplatelet agents. The results from our present study
would provide more clinical information when choosing the most
appropriate TRA for patients in view of the different prognosis for
patients with ACS or CAD.
Methods
Data Sources
An electronic literature search was performed using the following
search terms: platelet aggregation inhibitor, antiplatelet, acute
coronary syndrome (ACS), coronary artery disease (CAD), cardio-
vascular disease (CVD), atherosclerosis, atherothrombosis; dou-
ble-blind, placebo-controlled, randomised trials, RCT, (controlled)
clinical trial, with one of the following terms, thrombin-receptor
antagonist (TRA), protease-activated-receptor (PAR-1) antagonist,
atopaxar (E-5555), vorapaxar (SCH-530348), as extension in
Embase, MEDLINE, and Cochrane database from inception to
May 15, 2012. In addition, a manual search was carried out from
the identiﬁed bibliography.
Inclusion Criteria1. Studies should be reported in English.
2. All participants in the study should be explicitly diagnosed
with ACS or CAD (or at least include a subgroup of patients
diagnosed with CAD).3. Double-blind study should contain a placebo-controlled arm,
a minimal 20 patients in each group, and be of a duration of
12 weeks.4. Study should at least present the results regarding the major
adverse cardiovascular (CV) events (MACEs) and incidence of
bleeding according to thrombolysis in myocardial infarction
(TIMI) in each arm.
Data Extraction
Information extracted included study protocol, drug doses, treat-
ment duration, characteristics of participants, randomization and
blinding process, and intention-to-treat (ITT) and safety populations.
Primary outcomes included the incidence of MACEs (a composite
death from CV disease, MI, stroke, recurrent ischemia, or urgent
revascularization) and the incidence of bleeding events according to
TIMI (major, minor, minimal, or non-TIMI bleeding) (the deﬁnition of
TIMI bleeding is detailed in the Appendix in Supplemental Materials
found at http://dx.doi.org/10.1016/j.vhri.2015.01.003). Secondary out-
comes included adverse effects if applicable. Data were extracted
according to doses and the combined atopaxar/vorapaxar group (all
doses), respectively.
Two reviewers independently conducted the data extraction
process. Any discrepancies were resolved via discussion. Onlydata agreed by the two reviewers were included in the meta-
analysis.Data Analysis
The Revman 5.1 software was used to perform the meta-analysis.
Efﬁcacy outcomes were analyzed on the basis of the ITT pop-
ulation, whereas safety outcomes were analyzed on the basis of
the safety population. For deﬁnition, the ITT population is all
randomized patients who received at least one dose of study
medication and had at least one postbaseline assessment; the
safety population is all randomized patients who received at least
one dose of study medication. To compare the TRA with placebo,
we used random effects of the weighted Mantel-Haenszel
method to estimate pooled ORs and 95% CIs for each variable
according to the ACS or CAD cohort. In addition, because there
was no direct head-to-head comparative study of atopaxar and
vorapaxar, adjusted indirect comparisons based on the Bucher
frequentist method [8] were performed to compare primary
efﬁcacy and safety end points between atopaxar and vorapaxar.
Subgroup analyses were also conducted. Heterogeneity was
assessed via the I2 test, which measures the percentage of total
variation across studies due to heterogeneity. A percentage of
25%, 50%, and 75% indicates low, medium, and high heteroge-
neity, respectively [9].
Furthermore, to ascertain whether beneﬁts of TRA adminis-
tration outweigh risks, a risk-beneﬁt analysis was subsequently
conducted to calculate estimated averted CV events versus
bleeding events when 10,000 patients were treated by TRA
compared with placebo. Speciﬁcally, the number of MIs, strokes,
recurrent ischemias, CV deaths, and any bleeding events with or
without TRA was ﬁrst calculated. Then, each kind of averted CV
events was calculated by multiplying the rate for the placebo
group by (1  risk ratio) derived from our meta-analysis and then
by 10,000. The same approach was applied to estimate bleeding
events.Results
The electronic literature search initially yielded 514 articles, with
102 from MEDLINE, 7 from Cochrane Library, and 405 from
Embase, respectively. After screening the titles of the identiﬁed
studies, 348 were excluded because of irrelevance. Subsequently,
the remaining 166 articles were checked for eligibility on the
basis of abstracts. As a result, 24 articles met predeﬁned inclusion
criteria. Sixteen of these retrieved studies, however, were
excluded because they were health technology assessment stud-
ies [10] or reviews [11–18], were for nonhuman subjects [19,20],
investigated in vitro effect [21], carried out testing in healthy
volunteers [22,23], or focused on pharmacokinetics only [24,25],
leaving 8 randomized controlled trials (RCTs) as potentially
eligible. Furthermore, because one study was dedicated to inves-
tigate the therapeutic effect of vorapaxar for patients with a
history of ischemia stroke [26], it was excluded eventually. In all,
seven RCTs were ﬁnally included in our meta-analysis [27–33].
The selection and culling process is presented in Figure. 1,
whereas characteristics and quality evaluation of the included
RCTs are summarized in Table 1. Except for two studies [28,29], all
included studies were double-blinded and the method to accom-
plish randomization was mainly an interactive voice response
system.
We subdivided our meta-analysis according to different TRA-
administered cohorts (ACS or CAD); thus, the following results
were presented.
Fig. 1 – Study selection process. RCT, randomized controlled trial.
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Description
There were four RCTs that recruited patients with a diagnosis of ACS
[28,29,31,32]. Three of the studies included patients with acute
symptoms of newly onset coronary ischemia under similar diagnosis
criteria (new ST-segment depression of 40.1 mv or transient ST-
segment elevation of o30 minutes of 40.1 mV in at least two
contiguous leads; elevated levels of cardiac troponin I/T or creatine
kinaseMBwithin 24 hours before enrolment). Only one study had the
time period extended to 72 hours. Moreover, different loading doses
were arranged for participants after the randomization. Speciﬁcally,
for atopaxar, the loading dose was 400 mg in two studies [28,31]; for
vorapaxar, the loading dose was 20/40 mg [29] or 40 mg [32]. The
treatmentdurationvaried from12weeks tomore thanayear (Table 1).
Efﬁcacy End Points
Generally, efﬁcacy end points in the TRA treatment group showed a
favorable trend when compared with placebo. For instance, the OR
of MACEs was 0.80 (95% CI 0.52–1.22), with medium heterogeneity
detected. In terms of ORs for MI and stroke, the pooled effects still
favored TRA (OR 0.51, 95% CI 0.25–1.05, and 0.80, 95% CI 0.59–1.08,
respectively). When considering recurrent ischemia, however, TRA
was inferior to placebo, with an OR of 1.27 (95% CI 0.78–2.05). Whereapplicable, we synthesized the studies reporting events of CV death,
MI, or stroke. The heterogeneity of these variables ranged from low
to medium. Our syntheses showed that with respect to CV death,
TRA and placebo displayed equivalent efﬁcacies (OR 1.00; 95% CI
0.82–1.22). In contrast, the incidence of CV death, MI, or stroke was
lower in the TRA-treated group, with an OR of 0.88 (95% CI 0.77–1.00)
without heterogeneity (Fig. 2).Safety End Points
All the included studies adopted the incidence of bleeding as
their safety end point. The severity of bleeding was classiﬁed
according to TIMI (major, minor, minimal, or non-TIMI bleeding)
[34]. In addition, all the RCTs used a clinical evaluation commit-
tee to adjudicate the bleeding event to avoid potential bias.
Except for minimal bleeding (OR 0.89; 95% CI 0.53–1.47), events
of any TIMI bleeding, major bleeding, minor bleeding, and non-
TIMI bleeding were disappointingly higher in TRA-managed
patients, with ORs of 1.47 (95% CI 1.33–1.62), 1.55 (95% CI 1.25–
1.93), 1.59 (95% CI 1.20–2.11), and 1.37 (95% CI 1.24–1.51), respec-
tively, without heterogeneities (Fig. 3).
Three RCTs presented the incidence of adverse events
[28,29,31]. Not surprisingly, the incidence of adverse events was
lower in the placebo group, with an OR of 1.13 (95% CI 0.78–1.62)
(see Appendix in Supplemental Materials).
Table 1 – Characteristics of included studies.
Study ID Study
drug
Country Randomi-
zation
Methodology quality Treatment
and follow-
upBlindness Conceal-
ment
ITT
Acute coronary syndrome
Goto et al.
(2010) [28]
Atopaxar Japan Not clear Not clear Not clear Yes 12 and 4 wk
O’Donoghue
et al. (2011)
[31]
Atopaxar 22 countries Interactive voice
response system
Double
blinding
Adequate Yes 12 and 4 wk
184 sites
Goto et al.
(2010) [29]
Vorapaxar Japan Not clear Not clear Not clear Yes 60 and 0 d
Tricoci et al.
(2012) [32]
Vorapaxar 37 countries 24-h automated
voice response
system
Double
blinding
Adequate Yes Z1 y
818 sites
Coronary artery disease
Goto et al.
(2010) [28]
Atopaxar Japan Not clear Not clear Not clear Yes 24 and 4 wk
Wiviott et al.
(2011) [33]
Atopaxar 11 countries Not clear Double
blinding
Adequate Yes 24 and 4 wk
136 sites
Becker et al.
(2009) [27]
Vorapaxar USA Interactive voice
response system
Double
blinding
Adequate Yes 60 and 30 d
Morrow et al.
(2012) [30]*
Vorapaxar 32 countries Central
computerized
system
Double
blinding
Adequate Yes 24–36 mo
1032 sites
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[28,31]. The OR of pooled events of alanine transaminase levels
beyond 3 times of the upper limit of normal was 2.58 (95% CI 0.41–
16.17) compared with placebo, indicating that the number of
patients with abnormal liver function treated by TRA was higher.
Goto et al. [29] also reported the number of patients with
abnormal hepatic function (3 of 14 in the placebo group and 7
of 71 in the TRA group), although the deﬁnition of abnormal
hepatic disorder in that study was not speciﬁed (see Appendix in
Supplemental Materials).
Subgroup Analyses
The three dose levels of atopaxar used in the studies exerted
different effects on the incidence of MACEs and any bleeding
classiﬁed by TIMI. Surprisingly, the lowest dose (50 mg) had the
most preferable proﬁle in both MACEs and bleeding in terms of
ORs (0.64, 95% CI 0.28–1.47, and 0.80, 95% CI 0.43–1.51, respec-
tively), whereas the other two higher doses were inferior toplacebo in both variables (ORs were 1.24, 95% CI 0.61–2.51, and
1.25, 95% CI 0.70–2.20, and 1.04, 95% CI 0.50–2.20, and 1.02, 95% CI
0.49–2.12, respectively). All syntheses reported low to medium
heterogeneity.
Only one RCT took different doses of vorapaxar into consider-
ations (1 and 2.5 mg) [29], and the other just administered 2.5 mg to
patients with ACS [32]. Hence, only this higher dose (2.5 mg) was
synthesized in subgroup analysis. The results showed that events
of bleeding based on TIMI criteria were higher in vorapaxar-treated
patients than in placebo-treated patients (ORs 1.49; 95% CI 1.35–1.65;
I2 ¼ 0%) (see Appendix in Supplemental Materials).Coronary Artery Disease
Description
Four RCTs were included in this meta-analysis [27,28,30,33],
with treatment period varying from 60 days to 24 months. In
Table 1 – continued.
Doses (mg) and no. of
ITT population
Characteristics of participants
Age (y),
mean  SD
or IT or M*
Male (%) Weight
(kg)
DM
(%)
HT
(%)
Aspirin
(%)
Previous
PCI
PCI in
study
period
Placebo 61 64.5  9.8 82 66.0  12.2 27.9 73.8 100 7 90.2
50 54 65.4  8.0 87 63.5  12.3 40.7 77.8 96.3 13 85.2
100 65 66.3  8.5 80 63.8  12.5 32.3 81.5 96.9 13 83.1
200 61 63.8  8.9 73.8 65.3  14.4 36.1 75.4 98.4 12 90.2
Placebo 142 62.1  9.14 66.9 NA 20.7 71.4 97.8 In total NA
50 156 60.7  9.16 71.2 24.5 70.3 96.1 259
100 157 61.6  9.46 72.0 21.0 68.2 94.2
200 148 62.3  10.38 63.5 23.0 73.0 94.5
Placebo 21 65  11 76 67  12 52 81 100 NA 100
1.0 37 Active Active Active Active Active Active Active
2.5 34 64  9 80 65  10 52 75 100 100
Placebo 6471 58–72 71.8 70–92 31.4 71.0 96.9 1531 57.4
2.5 7473 58–71 72.0 70–93 31.5 70.1 96.4 1559 58.1
Placebo 66 65.4  7.2 83.3 66.3  11.8 95.5 80.3 100 55 NA
50 63 66.8  7.5 92.1 65.6  9.2 95.2 79.4 100 52
100 66 66.7  7.4 89.4 66.4  10.4 93.9 78.8 100 53
200 68 67.1  6.8 85.3 67.2  9.6 94.1 88.2 100 60
Placebo 176 63 76 86 63 NA 95 62 NA
50 182 64 75 90 71 90 63
100 174 62 75 90 64 95 62
200 186 64 78 89 69 91 66
Placebo 151 62.7  9.3 85 90.1618.7 32 NA 98 68 151
0.5 136 Active Active Active Active Active 208 136
1.0 139 64.5  9.8 74 89.219.2 36 99 139
2.5 138 138
Placebo 13224 53–69 76.2 NA 25.5 68.4 81.2–98.1 8620† NA
2.5 13225 53–69 76.0 25.4 69.0 80.7–98.1 8641†
IT, interquartile range; M, median; MI, myocardial infarction; NA, not available; PCI, percutaneous coronary intervention.
* This study enrolled all the patients with a history of atherosclerosis (including a spontaneous MI or ischemia stroke or peripheral artery
disease). Patients with any previous coronary artery disease and previous coronary revascularization accounted for 78.1% and 65.3% and
78.4% and 65.2% in the vorapaxar and placebo group, respectively.
† These ﬁgures included patients who underwent coronary-artery bypass grafting (CABG) [27].
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in two studies, while vorapaxar was administered at 0.5, 1.0, and
2.5 mg in one study [27] and at 2.5 mg in the other RCT [33]. Of the
four studies, three included only patients diagnosed with CAD,
while the other also enrolled patients with ischemia, stroke, or
peripheral artery disease [33]. Patients with previous CAD, how-
ever, accounted for the largest proportion of participants (478%
in each group). It is also worth mentioning that except for
patients in one study [27], subjects in the other three RCTs did
not undergo percutaneous coronary intervention during the
study period. This intervention might alter the prognosis of
patients because it was observed that early invasive approach
compared with a conservative approach in high-risk patients
with non–ST-segment elevation MI can improve clinicaloutcomes with a decrease in in-hospital death and recurrent MI
[35] (Table 1).
Efﬁcacy End Points
Overall, TRA-treated patients enjoyed a better proﬁle in all the
efﬁcacy end points. Particularly, the number of MACEs (OR 0.74;
95% CI 0.53–1.05), CV deaths, MIs, or strokes (OR 0.86; 95% CI 0.79–
0.94; MI: OR 0.82; 95% CI 0.74–0.92; stroke: OR 0.97; 95% CI 0.83–
1.14), CV deaths (OR 0.89; 95% CI 0.76–1.05), and recurrent
ischemias (OR 0.36; 95% CI 0.15–0.86) were all lower than in the
placebo-treated group. One study by Goto et al. [28] observed,
however, that during their 24-week treatment plus 4-week
follow-up period, the only MACE reported was recurrent ischemia
Fig. 2 – Pooled efﬁcacy effects (TRA vs placebo) for patients with ACS. ACS, acute coronary syndrome; CI, conﬁdence interval;
CV, cardiovascular; MACE, major adverse cardiovascular event; MI, myocardial infarction; TRA, thrombin-receptor antagonist.
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arms. Hence, this study was not included in the synthesis
pertaining to these variables.
With respect to heterogeneity, except for the pooled effects of
MACEs (P ¼ 0.24; I2 ¼ 28%), all the other variables did not show
any heterogeneity, indicating the consistency in results across
studies (Fig. 4).Safety End Points
In contrast to efﬁcacy end points, the events of bleeding classiﬁed
by TIMI were superior in the placebo arm. For instance, the ORs of
any TIMI bleeding, major bleeding, and minor bleeding were 1.48
(95% CI 1.37–1.59), 1.45 (95% CI 1.21–1.73), and 1.19 (95% CI 0.39–
3.68), respectively, without heterogeneity detected. Because no
Fig. 3 – Pooled safety effects (TRA vs placebo) for patients with ACS. ACS, acute coronary syndrome; CI, conﬁdence interval;
TIMI, thrombolysis in myocardial infarction; TRA, thrombin-receptor antagonist.
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not included in this synthesis [28] (Fig. 5).
Hepatic function was reported in two studies [28,33], with
alanine transaminase and enzymes aspartate transaminase levels
in both TRA-treated patients signiﬁcantly higher than in patients
treated with placebo. Speciﬁcally, the pooled ORs for patients whose
liver function parameters exceeded 3 times the upper limit of
normal level were 9.66 (95% CI 1.30–71.59) in case of ALT and 6.80
(95% CI 0.91–51.01) in case of AST, both without heterogeneities (see
Appendix in Supplemental Materials).
Subgroup Analysis
For atopaxar, with dose escalation, there was an upward trend in the
pooled effects of ORs for MACEs (ranged from 0.29 [95% CI 0.09–0.97]
to 0.59 [95% CI 0.23–1.56] with doses of 50–200 mg). In line with theefﬁcacy end point, bleeding events based on the TIMI classiﬁcation
showed that placebo was more preferable than TRA. Speciﬁcally, all
the three doses of atopaxar were inferior to placebo (ORs varied from
1.56 [95% CI 0.79–3.07] to 2.24 [95% CI 1.18–4.25]). The highest dose of
atopaxar (200 mg) generated the most effective outcome in MACEs
but was accompanied with the most bleeding incidence.
When it comes to vorapaxar, only the 2.5-mg dose was
explored in terms of events of TIMI bleeding by both studies.
Unfortunately, the incidence of bleeding was still higher in the
TRA-administered group, with an OR of 1.48 (95% CI 1.37–1.60)
(see Appendix in Supplemental Materials).
Risk-Beneﬁt Analysis
As a result, for the ACS cohort, total averted CV events were
459.87 with an excess of 438.82 bleeding episodes per 10,000
treated, which suggested that beneﬁts of TRA outweighed risks.
Fig. 4 – Pooled efﬁcacy effects (TRA vs placebo) for patients with CAD. CAD, coronary artery disease; CI, conﬁdence interval;
CV, cardiovascular; MACE, major adverse cardiovascular event; MI, myocardial infarction; TRA, thrombin-receptor antagonist.
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excess of 384.52 bleeding episodes per 10,000 treated. So, for the
latter cohort, the administration of TRA would result in excess
bleeding risk, and its use may need to be justiﬁed.Indirect Comparisons between Atopaxar and
Vorapaxar
The indirect comparison showed a superior trend in favor of
atopaxar over vorapaxar in the occurrences of any MACEs (ORs
0.93; 95% CI 0.38–1.32), MIs (ORs 0.52; 95% CI 0.13–0.95), and CVdeaths (ORs 0.82; 95% CI 0.12–4.24). Nevertheless, in terms of the
incidence of stroke and recurrent ischemia events, atopaxar
appears inferior to vorapaxar, with ORs of 1.26 (95% CI 0.15–
7.73) and 1.55 (95% CI 0.02–21.93), respectively. Most importantly,
atopaxar incurred less bleeding incidence as deﬁned by any TIMI
(ORs 0.69; 95% CI 0.29–2.78) than did vorapaxar (Table 2).Discussion
Even after strictly adhering to the recommended dual antiplatelet
treatment, the incidence of recurrent ischemia events, MIs,
Fig. 5 – Pooled safety effects (TRA vs placebo) for patients with CAD. CAD, coronary artery disease; CI, conﬁdence interval;
TIMI, thrombolysis in myocardial infarction; TRA, thrombin-receptor antagonist.
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with ACS or CAD was still persistently high. The inhibition of
protease-activated-receptor 1 by TRA may provide additional
beneﬁts in attenuating ischemic events [36,37]. From our meta-
analysis, we have several ﬁndings that may contribute to ascer-
taining the clinical position of TRA. First, for patients with ACS, a
promising ﬁnding from subgroup analyses was that the lowest
dose of atopaxar (50 mg) displayed more favorable proﬁles in
MACEs and bleeding events when using placebo as comparator.
Second, for patients with CAD, the only subgroup analysis
identiﬁed that the occurrence of bleeding was not greater in
those taking a higher dose of vorapaxar than in those taking a
combination of TRAs. Third, the indirect comparison suggested
that in terms of efﬁcacy end points, atopaxar might be more
preferable than vorapaxar in lowering the occurrence of MACEs,
MIs, and CV deaths, but may lead to a higher incidence of stroke
and recurrent ischemia events with lower bleeding risk. Last, on
comparing to the widely used clopidogrel (for CV events, OR 0.87;
95% CI 0.81–0.94; P o 0.01, compared with placebo plus aspirin),
results from the meta-analysis showed that these two new drugs
were comparable (Table 2).
Clinically speaking, the prognosis of ACS and CAD is diver-
gent. As reported by Alcock et al. [38], patients undergoing
percutaneous coronary intervention after a diagnosis of ACSTable 2 – Indirect comparison between atopaxar and vor
Drug MACEs MI Strok
Atopaxar 0.81 (0.49–1.33) 0.43 (0.19–0.99)* 1.17 (0.19–
Vorapaxar 0.87 (0.77–0.99)* 0.82 (0.71–0.96)* 0.93 (0.81–
Atopaxar vs
vorapaxar
0.93 (0.38–1.32) 0.52 (0.13–0.95)* 1.26 (0.15–
CI, conﬁdence interval; CV, cardiovascular; MACE, major adverse card
thrombolysis in myocardial infarction.
* Signiﬁcant results.had higher long-term mortality than did those with stable CAD.
In addition, for the population with ACS, contemporary interven-
tional and medical management strategies may effectively and
speciﬁcally counter the adverse prognostic impact of coronary
instability and myocardial damage [38]. As a result, the effect of
TRA should be analyzed on the basis of different diagnosis.
Speciﬁc to our study, it was observed that the effect of TRA on
primary efﬁcacy (MACEs) and safety (TIMI bleeding) end points
was similar for patients with ACS and CAD. Inconsistent with the
overall efﬁcacy end points, however, the occurrence of MI and
stroke was moderately better in the ACS cohort. In contrast, the
effect of improving the incidence of recurrent ischemia was
deﬁnitely better in the CAD cohort. Furthermore, with respect
to atopaxar, pooled effects displayed inconsistent results as to
the ACS and CAD cohorts. For atopaxar 50-mg dose, a different
effect on the incidence of MACEs was observed for the ACS and
CAD population, with better effect achieved in patients with CAD.
In contrast, the other two higher doses (100 and 200 mg) showed
contradictory results. In the ACS cohort, these two doses were
not superior to placebo at all, whereas in the CAD cohort, they
demonstrated more desirable effects in MACEs. The possible
interpretation for this divergence might be the difference in
response to TRA with respect to various cohorts. Furthermore,
as indicated in one study, the blood markers of thrombinapaxar (ORs , 95% CI)
e Recurrent
ischemia
CV death Any TIMI
7.22) 1.02 (0.21–4.93) 0.77 (0.15–4.00) 1.20 (0.81–1.77)*
1.07) 0.66 (0.10–4.45) 0.94 (0.83–1.06) 1.48 (1.39–1.57)*
7.73) 1.55 (0.02–21.93) 0.82 (0.12–4.24) 0.69 (0.29–2.78)
iovascular event; MI, myocardial infarction; OR, odds ratio; TIMI,
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patients receiving aspirin and clopidogrel and could predict an
increased likelihood of adverse clinical outcomes [39]. Because
the blood level of thrombin in patients with ACS may be varied
relative to that in patients with CAD, as the competitor for
thrombin to deprive protease-activated receptor, TRA may exert
a different effect on these two cohorts possibly owing to dissim-
ilar levels of thrombin. Overall, if our observation that patients
with CAD would beneﬁt more than would patients with ACS from
TRA treatment could be conﬁrmed by future clinical trials, the
cost-effectiveness proﬁle of TRA could be established for distinc-
tive target population. Besides the clinical implication, this would
be of signiﬁcant value for decision makers in formulating clinical
guidelines and resource allocation.
Nonetheless, the 95% CI of ORs (pertaining to efﬁcacy end
points for both ACS and CAD cohorts with low to median
heterogeneities) from our meta-analysis all included one for
either direct and indirect comparisons and thus would be
interpreted as demonstrating no statistically signiﬁcant differ-
ence compared with placebo. When performing the indirect
comparisons, the variance of individual study was combined to
estimate the variance for integrated outcomes, leading to a
greater variance than in the individual studies. Consequently,
the CIs for those outcomes were even larger and showed no
statistical signiﬁcance. For the direct comparisons, this observa-
tion of no signiﬁcance has to be interpreted together with two
factors, namely, duration of the trials and intent of the trials.
First, the varying duration of the included RCTs primarily
accounted for the large variance in the ﬁnal results. Particularly,
the duration for ﬁve of the included RCTs varied from 12 weeks to
24 weeks while the other two RCTs lasted for 502 days (median)
and 3 years, respectively. Because the MACEs require various
time to progress or present (e.g., 1 in 10 patients experienced a
major ischemic outcome within 1 year of an ACS even with the
dual antiplatelet therapy) [4,40] and long-term medication man-
agement is irreplaceable, the short duration of some of our
included trials may fail to catch the TRA’s beneﬁts in decreasing
the incidence for these events [27–29,31,33].
This leads to the second factor about the intent of the
included trials. It is well accepted that in clinical setting, when
we attempt to evaluate an antiplatelet agent, safety is always the
priority concern. Hence, the included studies with a treatment
duration of 12 to 24 weeks would provide information to address
this concern and probably designed with this as one if not the
main objective. As demonstrated in our meta-analysis, the
pooled ORs for the primary safety end point (deﬁned as any TIMI)
were 1.47 (95% CI 1.33–1.63) and 1.48 (95% CI 1.37–1.59) for
patients with ACS and CAD, respectively, when TRA was com-
pared with placebo. Therefore, it is important to determine
whether patients can obtain net beneﬁt from the treatments.
As a result, the risk-beneﬁt analysis favors the use of TRA in
patients with ACS rather than in those with CAD. So for the latter
cohort, the administration of TRA would result in excess bleeding
risk, and its use may need to be justiﬁed.
After satisfying the safety and efﬁcacy demands, another
major issue is to determine the cost-effectiveness proﬁle of these
speciﬁc medications. Because lifetime preventive treatment is
needed for patients with a history of ACS or CAD, it is imperative
to ascertain the long-term treatment cost-effectiveness for the
administration of TRA. With an appropriate modeling method,
the efﬁcacy outcomes presented in our study may be extrapo-
lated to evaluate the long-term cost-effectiveness of TRA. Last
but not the least, even though future RCTs with a larger number
of subjects and longer duration would be the best solution to
address the efﬁcacy, safety, and cost-effectiveness proﬁle of TRA,
our study could be the best substitution based on the available
evidence at the moment.Inherently, several limitations of our present study should
also been noted. First, the treatment durations of included
studies varied substantially, ranging from 12 weeks to more
than 2 years. It is not uncommon for a patient with ACS or CAD
to take antiplatelets for a long term; therefore, the short time
period cannot adequately capture differences in MACEs or
safety proﬁle attributable to a treatment. However, not all
patients with ACS or CAD underwent percutaneous coronary
intervention during the study period although percutaneous
coronary intervention may alter the prognosis of ACS or CAD to
a certain extent.Conclusions
Our study showed that the two kinds of TRAs might be more
effective than placebo in improving the incidence of MACEs but
with a higher risk of TIMI bleeding and hepatic disorder. Further-
more, the TRA may exert different effects in patients with ACS or
CAD, especially for the occurrence of MIs, strokes, and recurrent
ischemias. Results from the indirect comparison showed that
atopaxar might be more preferable to vorapaxar but this would
need to be conﬁrmed by future head-to-head studies.Supplemental Materials
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